Trial Profile
A retrospective study to evaluate the safety and efficacy of daratumumab in patients with multiple myeloma after allogeneic stem cell transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2017
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
- 20 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.